Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common driver oncogene in human cancers; it is an essential mediator of tumor cell growth and survival1 and is often associated with poor outcomes.2,3 More than three decades of efforts to target KRAS downstream signaling pathways in KRAS-mutated cancers have largely been ineffective.4 This evidence concerns the gene KRAS and neoplasm.